Lumigan is a brand name of bimatoprost ophthalmic, approved by the FDA in the following formulation(s):
LUMIGAN (bimatoprost - solution/drops; ophthalmic)
Manufacturer: ALLERGAN
Approval date: March 16, 2001
Strength(s): 0.03% [RLD]
Manufacturer: ALLERGAN
Approval date: August 31, 2010
Strength(s): 0.01% [RLD]
Has a generic version of Lumigan been approved?
No. There is currently no therapeutically equivalent version of Lumigan available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lumigan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
Patent 5,688,819
Issued: November 18, 1997
Inventor(s): Woodward; David F. & Andrews; Steven W. & Burk; Robert M. & Garst; Michael E.
Assignee(s): Allergan
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.Patent expiration dates:
- August 19, 2014✓
- August 19, 2014✓
- August 19, 2014
Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
Patent 6,403,649
Issued: June 11, 2002
Inventor(s): David F.; Woodward & Steven W.; Andrews & Robert M.; Burk & Michael E.; Garst
Assignee(s): Allergan Sales, Inc.
The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cydopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.Patent expiration dates:
- September 21, 2012✓✓✓
- September 21, 2012✓✓
- September 21, 2012
Enhanced bimatoprost ophthalmic solution
Patent 7,851,504
Issued: December 14, 2010
Inventor(s): Chang; Chin-Ming & Chang; James N. & Schiffman; Rhett M. & Jordan; R. Scott & Chang-Lin; Joan-En
Assignee(s): Allergan, Inc.
A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Patent expiration dates:
- June 13, 2027✓✓
- June 13, 2027
Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
Patent 8,017,655
Issued: September 13, 2011
Inventor(s): Woodward; David F. & Andrews; Steven W. & Burk; Robert M. & Garst; Michael E.
Assignee(s): Allergan, Inc.
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.Patent expiration dates:
- November 27, 2012✓✓
- November 27, 2012
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- August 31, 2013 - NEW PRODUCT
See also...
- Lumigan Consumer Information (Drugs.com)
- Lumigan Drops Consumer Information (Wolters Kluwer)
- Lumigan Consumer Information (Cerner Multum)
- Lumigan Advanced Consumer Information (Micromedex)
- Lumigan AHFS DI Monographs (ASHP)
- Bimatoprost Drops Consumer Information (Wolters Kluwer)
- Bimatoprost ophthalmic Consumer Information (Cerner Multum)
- Latisse Advanced Consumer Information (Micromedex)
- Bimatoprost Ophthalmic Advanced Consumer Information (Micromedex)
- Bimatoprost AHFS DI Monographs (ASHP)
No comments:
Post a Comment